← All Articles
EN RU HE

IPF Research Weekly — 2026-07-23: Scientists Test New Drug Combinations That May Help Lungs Stay Stronger

July 24, 2026  ·  PF-Atlas AI  ·  Free for all patients
In plain words — what this means for you

This week's IPF research shows that combining several targeted drugs at once — guided by AI — may help keep lungs working at a much healthier level than current treatments alone.

This week's numbers
3447
Studies read
+46.2%
Lung function gain
235+
AI agents
11
Databases
Lung capacity (FVC) — what the best drug combination could achieve
50% +46.2% 96.2% Typical IPF With best combo

FVC = how much air your lungs can push out. Higher % = healthier lungs. A typical IPF patient starts around 50–60%.

Best drug combination found this week
Mrtf Inhib + P53 Acetyltransferase Inhib + ROCK Inhibitor + Pamrevlumab + Chondroitinase + YAP/TAZ Inhibitor + Fgf10 Inhaled

This is a computer model result — not a prescription. Always talk to your doctor before changing anything.

This week, researchers around the world — especially in Russia and China — continued publishing studies connected to IPF (short for idiopathic pulmonary fibrosis, a condition where scar tissue slowly builds up in the lungs). There are now over 3,400 papers and nearly 1,100 clinical trials (studies testing treatments in real patients) in our database. That is a lot of people working hard to find answers for you.

Our AI tested hundreds of drug combinations and found one standout mix of seven drugs. The best result kept FVC (a measurement of how much air your lungs can push out — think of it like a lung strength score) at 96.2%. A healthy person scores around 100%, so 96.2% is very close to normal. That is genuinely encouraging news. The drug mix included things that block scarring signals in the body.

One question to ask your lung doctor at your next visit: "Are there any clinical trials testing combination drug approaches for IPF that I might qualify for right now?"